In this non-comparative , open-label , randomised phase 2 trial , we recruited patients with locally advanced ( non-resectable ) or metastatic cholangiocarcinoma , gallbladder carcinoma , or ampullary carcinoma and a WHO performance status of 0 or 1 from 18 hospitals across France and Germany .